Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

Autor: Odia Y; Department of Neuro-Oncology, Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, USA., Koschmann C; Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA., Vitanza NA; The Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA.; Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, Washington, USA., de Blank P; Department of Pediatric Neuro-Oncology, University of Cincinnati Medical Center, Cincinnati, Ohio, USA., Aguilera D; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Allen J; Department of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA., Daghistani D; Department of Neuro-Oncology, Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, USA., Hall M; Department of Neuro-Oncology, Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, USA.; Department of Radiation Oncology, Nicklaus Children's Hospital, Miami, Florida, USA., Khatib Z; Department of Radiation Oncology, Nicklaus Children's Hospital, Miami, Florida, USA., Kline C; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., MacDonald T; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Mueller S; Department of Clinical Pediatrics and Neurosurgery, University of California, San Francisco; California, USA., Faison SL; Certara Inc., Princeton, New Jersey, USA., Allen JE; Chimerix, Inc, Durham, North Carolina, USA., Naderer OJ; Chimerix, Inc, Durham, North Carolina, USA., Ramage SC; Chimerix, Inc, Durham, North Carolina, USA., Tarapore RS; Chimerix, Inc, Durham, North Carolina, USA., McGovern SL; Department of Pediatric Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Khatua S; Department of Pediatric Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA., Zaky W; Department of Pediatric Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gardner SL; Department of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2024 May 03; Vol. 26 (Supplement_2), pp. S155-S164.

Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage.

Autor: Naderer OJ; GlaxoSmithKline, Research Triangle Park, North Carolina, USA., Rodvold KA, Jones LS, Zhu JZ, Bowen CL, Chen L, Dumont E

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014; Vol. 58 (1), pp. 419-23. Date of Electronic Publication: 2013 Nov 04.